2nd EYES meeting, Belgrade, Serbia - registration and abstract submission now open

Exelixis gains European Cometriq nod with note about low response in non-RET mutated MTC patients (Pharmacogenomics Reporter, 25 March 2014)

Pfizer achieves primary endpoint with phase 3B top-line results of Genotropin in very young children born small for gestational age (Business Wire, 26 March 2014)

26 Mar 2014

Pfizer reports top-line results from a Phase 3B study evaluating the 24-month efficacy of Genotropin (somatropin) on height in small-for-gestational-age children at 24-30 months old.

Share this story

Top stories

Call for nominations for Awards Committee Chair
30 Oct 2024

James M Tanner Award - 2025 nominations open
30 Oct 2024

Would you like to host the BSPED annual meeting?
21 Oct 2024

Most read